Nomura I, Takechi H, Kato N. Intraneuronally injected amyloid beta inhibits long-term potentiation in rat hippocampal slices. J Neurophysiol 107: 2526 -2531, 2012. First published February 15, 2012 doi:10.1152/jn.00589.2011.-Extracellular accumulation of amyloid beta (A) is a hallmark of Alzheimer's disease (AD). It has been reported that extracellular perfusion of A inhibits long-term potentiation (LTP), which is strongly related to memory in animal models. However, it has recently been proposed that intracellular A may be the first pathological change to occur in AD. Here, we have investigated the effect on LTP of intracellular injection of A (A 1-40 , A 1-42 ) into hippocampal pyramidal cells using patch-clamp technique. We found that injection of 1 nM A 1-42 completely blocked LTP, and extracellular perfusion of a p38 MAPK inhibitor or a metabotropic glutamate receptor blocker reversed these blocking effects on LTP. Furthermore, we have examined the effects of different concentrations of A 1-40 and A 1-42 on LTP and showed that A 1-40 required a 1,000-fold higher concentration to attenuate LTP than 1 nM A 1-42 . These results indicate that LTP is impaired by A injected into genetically wild-type neurons in the sliced hippocampus, suggesting an acute action of intracellular A on the intracellular LTP-inducing machinery.Alzheimer's disease; p38 MAPK; metabotropic glutamate receptor; whole cell patch clamp ALZHEIMER'S DISEASE (AD) is a neurodegenerative disorder characterized by progressive cognitive impairment. In AD pathology, beta-amyloid (A), a peptide generated in the neuron and secreted extracellularly, is believed to be among the most pathological factors leading to neurodegeneration, membrane disruption, oxidative stress, impaired mitochondrial activity, synaptic dysfunction, and disturbance of axonal trafficking (Crouch et al. 2008).